Payment overview · 2025
General Payments
$664.54
34 reported records · 11 companies
Healthcare provider profile · identity verified
Michael T. Snitzer, M.D. LTD
Allopathic & Osteopathic Physicians|Internal Medicine · WARREN, OH · NPI 1619955796
Verified facts
What the public records show
CMS Open Payments records show Michael T. Snitzer, M.D. LTD received $664.54 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $284.93 | 42.9% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.38 | 10.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.81 | 9.2% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.62 | 8.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.30 | 8.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.94 | 5.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.36 | 3.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.04 | 3.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $21.31 | 3.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.39 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.46 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.54 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $234.20 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $152.64 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.30 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.62 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.64 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 144 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
175 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 752 | 213 |
| Atorvastatin Calcium | Atorvastatin Calcium | 547 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 500 | 147 |
| Losartan Potassium | Losartan Potassium | 422 | 120 |
| Lisinopril | Lisinopril | 375 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 359 | 116 |
| Omeprazole | Omeprazole | 356 | 105 |
| Lorazepam | Lorazepam | 319 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 308 | 104 |
| Simvastatin | Simvastatin | 268 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 76 |
| Tramadol Hcl | Tramadol Hcl | 248 | 51 |
| Alprazolam | Alprazolam | 239 | 53 |
| Sertraline Hcl | Sertraline Hcl | 238 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 218 | 67 |
| Furosemide | Furosemide | 210 | 80 |
| Synthroid | Levothyroxine Sodium | 175 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 53 |
| Potassium Chloride | Potassium Chloride | 174 | 58 |
| Atenolol | Atenolol | 161 | 51 |
| Gabapentin | Gabapentin | 155 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 36 |
| Metformin Hcl | Metformin Hcl | 145 | 50 |
| Eliquis | Apixaban | 144 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 41 |
| Allopurinol | Allopurinol | 116 | 34 |
| Glimepiride | Glimepiride | 112 | 36 |
| Metformin Hcl Er | Metformin Hcl | 104 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 26 |
| Meloxicam | Meloxicam | 85 | 28 |
| Azithromycin | Azithromycin | 84 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 19 |
| Warfarin Sodium | Warfarin Sodium | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 19 |
| Finasteride | Finasteride | 49 | 13 |
| Clonidine Hcl | Clonidine Hcl | 46 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | 15 |
| Temazepam | Temazepam | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 11 |
| Clonazepam | Clonazepam | 43 | 11 |
| Celecoxib | Celecoxib | 41 | 13 |
| Valsartan | Valsartan | 41 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 13 |
| Jardiance | Empagliflozin | 39 | 15 |
| Ezetimibe | Ezetimibe | 37 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 11 |
| Jantoven | Warfarin Sodium | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Spironolactone | Spironolactone | 31 | 12 |
| Amoxicillin | Amoxicillin | 30 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Famotidine | Famotidine | 25 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Prednisone | Prednisone | 20 | 14 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.54 · 34 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAMZYOS, ELIQUIS, FREESTYLE LIBRE 3, INSPIRE, Kerendia, Korlym, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, UNITHROID, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error